根据受体状态的局部晚期可手术乳腺癌发生率模式的变化:SEER 2010-2021年
Alexandra Thomas1, Anthony Rhoads2, Erica L Mayer3
1Duke Cancer Institute, Duke University, Durham, NC, USA. alexandra.thomas@duke.edu.
NPJ breast cancer
|November 13, 2025
概括
瘤生物风险指导HR阳性乳腺癌的化疗. 晚期结节疾病 (N2-3) 的发生率下降,而HR-阳性/HER2-阴性病例中较大的瘤 (T3-4) 的发生率增加.
科学领域:
- 在瘤学瘤学.
- 乳腺癌研究研究 乳腺癌研究
- 癌症流行病学 癌症流行病学
背景情况:
- 瘤生物风险越来越多地被用于HR阳性早期乳腺癌的化疗决策,而不是解剖学阶段.
- 手术试验表明下淋巴结解剖减少,可能改变N2-3诊断率.
- 基因组风险评估正在考虑局部发达,可手术的HR阳性乳腺癌.
研究的目的:
- 估计当前局部晚期,可手术的HR-阳性乳腺癌的发病率,重点关注HR-阳性/HER2-阴性疾病.
- 分析该人口中N2-3M0和T3-4N0-1M0疾病发病率的趋势.
- 了解侵袭性叶状腺癌在局部晚期HR-阳性/HER2-阴性乳腺癌中的作用.
主要方法:
- 利用了美国国家癌症研究所的监测,流行病学和最终结果-17数据库 (2010-2021).
- 分析了486,031例I-III期HR阳性/HER2阴性乳腺癌病例.
- 计算了N2-3M0 ((任何T) 和T3-4N0-1M0疾病亚型的发病率.
主要成果:
- 在486,031例中,5.9%的人患有N2-3M0 (任何T),4.8%的人患有T3-4N0-1M0疾病.
- 侵袭性分叶癌在HR阳性/HER2阴性局部晚期疾病中最为普遍.
- 在各个亚型中,N2-3M0 ((任何T) 的发生率下降,而在HR阳性/HER2阴性疾病中,T3-4N0-1M0的发生率增加.
结论:
- 确定化学疗法对局部晚期,可手术的HR阳性乳腺癌的益处仍然是一个关键的临床挑战.
- 改变诊断标准和治疗方法可能会影响观察到的发病率趋势.
- 需要进一步的研究,以优化治疗策略,基于风险分层在这个患者群体.
相关概念视频
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
01:21Cancer Survival Analysis
634
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
634